Research programme: targeted cancer therapeutics - Avidity BiosciencesAlternative Names: Antibody-siRNA complexes; Antibody-siRNA conjugates; ASC™
Latest Information Update: 11 Jan 2017
At a glance
- Originator Avidity NanoMedicines
- Developer Avidity Biosciences
- Class Recombinant fusion proteins
- Mechanism of Action Cell modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 17 Jun 2014 Early research in Cancer in USA (unspecified route)